Teva Pharmaceutical Industries Ltd. (Nyse and Tase: Teva) Hero a “day of innovation and strategy” today, in which he discussed the future of his biopharmaceutical (non -generic) activity. The company sees income from its three main drugs: Austedo, to treat involuntary movements; AJOVY migraine prevention treatment; and Uzedy of prolonged action schizophrenia treatment, which reaches at least $ 5 billion by 2030. This is compared with $ 2 billion for the three products combined in 2024.
The company has confirmed its orientation for 2027. It expects an operational margin or 30%, compared to 13.3% in the first quarter of 2025, thanks to its existing innovative products and those that are online to enter the market saving its saving of $ 700 million. Free cash flow is expected to reach $ 2.7 billion in 2027 and $ 3.5 billion in 2030.
URI Hershkovitz, manager of the Bennu Pharma Coverage Fund and TEVA analyst, said the guide was strong and that the market expected this, with the participation by increasing some in the five previous sessions. Today, the action closed 1.57% discount. The company has a market capitalization of just over $ 20 billion.
The CEO of Teva, Richard Francis, said the company had added $ 1 billion to its innovative revenues in the two years since it touched the position and broke the glass ceiling attributed to Austedo. According to the company, this product could reach income of $ 2.5 billion in 2027 and $ 3 billion in 2030. The Teva guide is largely based on this product.
Francis added that when he arrived in Teva, he felt the skepticism of the market about the company’s ability to return to innovative leadership. Since then, he said, a new product, Uzedy, had launched the leg, and the positive results had been worked in advanced clinical trials or two other products.
Teva plans to present a second treatment of prolonged action schizophrenia, Olanzapina, for the approval of the United States Food and Drug Administration (FDA) in the second or 2025. Go to Duvakitug, a treatment for the inflammatory disease of the bullet, the expansion of the expansion of the motimatient expansion of MottialSwow, expansion of the expansion of Wheatieses, WHEATIENES. of Wheatieveesses of Wheatieveveesses. Wheatieswowessessesseesewwwweweasion’s whey stcanssessessessessesessessesSwowwowSehiSion StcansasesesaSesesion’s Wheatieve, Wheatieve Stentieves, Expansis, stagnant expansion with an expansion mentality. It is at the end of 2024, with a maximum sales potential or up to $ 2-5 billion. Dari, a double action rescue inhaler for asthma found in phase 3 tests, has a maximum sales potential or around $ 1 billion.
The emusolmina, which Teva describes as “a potential treatment of the first in its class for the atrophy of the multiple system, a strange and fatal neuro-oenerative disease that currently does not have approved treatments”, it looks like a peak potential of more than, the peak that, which, so it has a peak of those that is coming by the peak that, in light, is presented in light. The company’s treatment for Celiac, to which the FDA granted the designation of fast road, is achieved in more than $ 1 billion.
Teva recycling debt after the qualification update
Teva will fire about 250-300 employees in Israel
Teva in progress for 2027 objectives
Francis said that would be the launch after the launch, not only of five plans, but of five drugs, some of which were for several indications. He said that the potential was simply greater than it seemed, and amounted to $ 10 billion, Althegh added that they were not large chains of patents on the horizon. In generic, the potential is for the launch of five new biosimilar products by 2027, in addition to the existing thirteen.
Posted by Globes, Israel Business News – Y.globes.co.Il – on May 29, 2025.
© Copyright of Globes Editor Itonut (1983) Ltd., 2025.
